Exeltis USA v. Glenmark: Contraceptive Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Exeltis USA, Inc. v. Glenmark Pharmaceuticals |
| Case Number | 2:25-cv-17250 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Nov 2025 – Mar 2026 124 days |
| Outcome | Plaintiff Win — Dismissal with Prejudice |
| Patents at Issue | |
| Accused Products | Glenmark’s ANDA-referenced generic drospirenone products and contraceptive kits. |
Case Overview
The Parties
⚖️ Plaintiff
U.S. commercial arm of Chemo Group, marketing SLYND® (drospirenone 4 mg), a progestin-only oral contraceptive approved by the FDA.
🛡️ Defendant
Multinational generic pharmaceutical manufacturer with an established U.S. presence through Glenmark Pharmaceuticals Inc., USA.
Patents at Issue
This case involved an exceptionally broad portfolio of **18 U.S. patents** asserted by Exeltis, spanning multiple patent families and filing generations, all protecting SLYND® (drospirenone).
- • US9603860B2 — Drospirenone formulations
- • US10179140B2 — Pharmaceutical compositions
- • US10603281B2 — Contraceptive kit configurations
- • US10849857B2 — Methods of administration
- • US10987364B1 — Synthetic progestogens
- • US11123299B2 — Drug formulations and uses
- • US11291632B2 — Extended release compositions
- • US11291633B2 — Contraceptive methods
- • US11351122B1 — Tablet compositions
- • US11413249B2 — Oral contraceptives
- • US11439598B2 — Drospirenone dosage forms
- • US11452695B2 — Regimens for contraception
- • US11478487B1 — Pharmaceutical kits
- • US11491113B1 — Methods of contraception
- • US11504334B2 — Drospirenone for continuous use
- • US11951213B2 — Pharmaceutical compositions
- • US12090231B2 — Dosing regimens
- • US12280151B2 — Packaging and administration
Developing a similar pharmaceutical product?
Check if your formulation or method might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case concluded via **stipulated dismissal with prejudice** pursuant to agreement between both parties. The dismissal covered all claims and all defenses in their entirety. Critically, the parties agreed to bear their own costs and attorneys’ fees — a mutual walk-away structure that neither confirms infringement nor establishes invalidity as a matter of public record. Specific financial terms, licensing arrangements, or ANDA-related agreements were not publicly disclosed.
Verdict Cause Analysis
The operative cause was an **infringement action** under the Hatch-Waxman Act, in which an ANDA filing by a generic manufacturer constitutes a statutory act of infringement upon which a brand-name patent holder may sue prior to product launch. This framework creates a structured 30-month stay of FDA approval — providing Exeltis with a powerful incentive to litigate even where the ultimate commercial risk is prospective rather than immediate.
The breadth of the asserted patent portfolio — 18 patents spanning formulation, composition, kits, and method claims across multiple patent families — is itself a litigation signal. Assembling such a portfolio maximizes claim surface area, complicates Glenmark’s invalidity and non-infringement analysis, and increases the cost and complexity of a contested defense.
Legal Significance
While this dismissal does not establish binding precedent on claim construction, validity, or infringement, it contributes to the observable pattern in pharmaceutical patent litigation where densely layered patent estates around blockbuster or differentiated products create substantial barriers to generic entry — barriers that frequently resolve in negotiated outcomes rather than adjudicated verdicts.
The case also reflects the continued strategic value of continuation patent practice: several of the 18 asserted patents share application lineages, suggesting an intentional prosecution strategy designed to extend and diversify claim coverage over time.
Freedom to Operate (FTO) Analysis in Pharma
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation in the contraceptive space.
- View all 18 asserted patents and their family trees
- Identify key claim features and their protective scope
- Understand the landscape of progestin-only contraceptives
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own pharmaceutical formulation or pipeline product.
- Input your product description or technical features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Drospirenone formulations & administration methods
18 Asserted Patents
Complex multi-family portfolio
Strategic Resolution
Negotiated outcome avoids adverse precedent
✅ Key Takeaways for Pharma IP
An 18-patent assertion across multiple continuation families signals deliberate prosecution strategy designed to maximize ANDA negotiating leverage.
Search related case law →Dismissal with prejudice and mutual cost-bearing is consistent with a negotiated license or entry-date agreement — terms worth monitoring for public disclosure.
Explore precedents →Frequently Asked Questions
Exeltis asserted 18 U.S. patents (including US9603860B2 through US12280151B2) covering drospirenone formulations, contraceptive compositions, pharmaceutical kits, and methods of administration related to SLYND®.
The parties stipulated to dismissal with prejudice of all claims and defenses, without costs or attorneys’ fees, consistent with a negotiated resolution. Specific settlement terms were not publicly disclosed.
It reinforces the strategic value of deep continuation patent portfolios in Hatch-Waxman disputes and signals that multi-patent assertions against ANDA filers in the contraceptive space can drive early negotiated resolution.
Ready to Strengthen Your Pharmaceutical Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharmaceutical sector.
References
- PACER Case Locator — Case No. 2:25-cv-17250 (D.N.J.)
- FDA Orange Book — SLYND® (drospirenone)
- USPTO Patent Full-Text Database (e.g., US9603860B2)
- Cornell Legal Information Institute — Hatch-Waxman Act
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.